AX Form 4: Gregory Garrabrants Receives 193,811 Restricted Stock Units
Rhea-AI Filing Summary
Gregory Garrabrants, President and Chief Executive Officer of Axos Financial, Inc. (AX), was granted 193,811 restricted stock units (RSUs) on 09/05/2025 under the Axos Financial, Inc. 2014 Stock Incentive Plan as part of his employment contract. Each RSU represents a contingent right to receive one share of common stock, and the award vests over four years with one-fourth vesting on each fiscal year-end following the grant date. After the grant, the filing reports direct beneficial ownership of 594,779 shares. The RSUs carry a reported price of $0.0, indicating no cash purchase price shown on the Form 4.
Positive
- Grant of 193,811 RSUs to the CEO documented on Form 4
- RSUs convert one‑for‑one into common stock, clarifying the equity linkage
- Vesting over four years (one‑fourth per fiscal year‑end) provides a clear retention schedule
- Reported direct beneficial ownership of 594,779 shares after the grant
Negative
- None.
Insights
TL;DR: CEO received a time‑vested equity award consistent with standard retention and alignment practices for senior executives.
The Form 4 documents a grant of 193,811 RSUs to the CEO under the company’s 2014 plan with four‑year annual vesting. This structure ties long‑term compensation to equity ownership and aligns the CEO’s realized compensation with future stock performance. The filing shows the award as contingent RSUs convertible one‑for‑one into common shares and reports total direct beneficial ownership of 594,779 shares following the grant. No additional compensation terms, performance conditions, or cash payments are disclosed in the filing.
TL;DR: A significant equity grant was issued that vests annually over four years; details are limited to vesting schedule and share counts.
The disclosure specifies the grant amount (193,811 RSUs), one‑to‑one share conversion, and a four‑year vesting schedule (one‑fourth each fiscal year‑end). The Form 4 does not disclose additional performance criteria, acceleration terms, or grant valuation. The reported price is $0.0, consistent with RSUs that do not require cash exercise. The filing is informative on quantity and vesting but omits other compensation mechanics that would affect pay‑for‑performance assessment.